Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

The combination of trastuzumab deruxtecan (Enhertu) with pertuzumab (Perjeta) as a first-line treatment for HER2-positive advanced metastatic breast cancer has been shown to reduce the risk for ...

aDepartment of Gastrointestinal Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada bDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer ...

That trial, DESTINY-Gastric05, is comparing the Enhertu-based combination to standard first-line treatment with Herceptin, Keytruda, and chemo. The DESTINY-Gastric04 results also highlight the need to ...

1 The approval of the combination therapy was based on data from the phase 3 Study AK105-304 (NCT04974398), which showed a statistically significant improvement in median progression-free survival ...